PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2168443

Thyroid-stimulating antibody activity between different immunoglobulin G subclasses.

A P Weetman·M E Yateman·P A Ealey·C M Black·C B Reimer·R C Williams·B Shine·N J Marshall
View original source ↗Export metadata ↓

Abstract

To investigate the distribution of thyroid-stimulating antibody (TSAb) activity between IgG subclasses, sera from 11 patients with Graves disease (including the National Institute of Biological Standards and Control (NIBSC) Research Standard, long acting thyroid stimulator-B) were fractionated by chromatography on affinity columns of monoclonal IgG subclass antibodies or protein A to deplete all but a single subclass. The resulting fractions were 98% or more pure for a single subclass. In all 11 patients, TSAb activity appeared to be confined to the IgG1 fraction as determined by cAMP production on addition of the fractions to the FRTL-5 rat thyroid cell line. In all of eight specimens from seven patients so tested, the whole serum activity was recovered in the IgG1 fraction, after adjusting for the recovery of the isotype from the column. TSAb activity in one serum comprised both lambda and kappa light chains but was IgG1 restricted. This IgG subclass restriction was not found when the same fractions were tested for thyroglobulin, microsomal/thyroid peroxidase, or tetanus toxoid antibody activity. Together with previous results showing marked restriction of both light chain usage and isoelectric point of TSAb, these results support the idea that Graves' disease may be the result of an oligo- or possibly monoclonal response at the B cell level.

Explore related subjects

Cyclic AMPGraves DiseaseHumansImmunoglobulin GIodide PeroxidaseReceptors, ThyrotropinTetanus ToxoidThyroglobulinThyroid GlandJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A P Weetman, M E Yateman, P A Ealey, C M Black, C B Reimer, R C Williams, B Shine, N J Marshall. 1990. Thyroid-stimulating antibody activity between different immunoglobulin G subclasses.. https://doi.org/10.1172/jci114768

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Effect of salt bridge on transcription activation of CRP-dependent lactose operon in Escherichia coli.

Expression of catabolite-sensitive operons in Escherichia coli is cAMP-dependent and mediated through the CRP:cAMP complex binding to specific sequences in DNA. Five specific ionic or polar interactions occur in cAMP binding pocket of CRP. E72 interacts with the cAMP 2' OH, R82 and S83 interact with the negatively charged phosphate moiety, and T127 and S128 interact with the adenine ring. There is evidence to suggest that E72 and R82 may mediate an essential CRP molecular switch mechanism. Therefore, stimulation of CRP transcription activation was examined by perturbing these residues. Further, CRP:cAMP complex was treated with a specific DNA sequence containing the lac CRP binding site along with RNA polymerase to mimic in vivo conditions. Biochemical and biophysical results revealed that regulation of transcription activation depends on alignment of CRP tertiary structure through inter-domain communication and it was concluded that positions 72 and 82 are essential in the activation of CRP by cAMP.

Cyclic AMP↗
PubMed2006

Different nucleobase orientations in two cyclic 2',3'-phosphates of purine ribonucleosides: Et(3)NH(2',3'-cAMP) and Et(3)NH(2',3'-cGMP)xH(2)O.

The crystal structures of triethylammonium adenosine cyclic 2',3'-phosphate {systematic name: triethylammonium 4-(6-aminopurin-9-yl)-6-hydroxymethyl-2-oxido-2-oxoperhydrofurano[3,4-c][1,3,2]dioxaphosphole}, Et(3)NH(2',3'-cAMP) or C(6)H(16)N(+).C(10)H(11)N(5)O(6)P(-), (I), and guanosine cyclic 2',3'-phosphate monohydrate {systematic name: triethylammonium 6-hydroxymethyl-2-oxido-2-oxo-4-(6-oxo-1,6-dihydropurin-9-yl)perhydrofurano[3,4-c][1,3,2]dioxaphosphole monohydrate}, [Et(3)NH(2',3'-cGMP)].H(2)O or C(6)H(16)N(+).C(10)H(11)N(5)O(7)P(-).H(2)O, (II), reveal different nucleobase orientations, viz. anti in (I) and syn in (II). These are stabilized by different inter- and intramolecular hydrogen bonds. The structures also exhibit different ribose ring puckering [(4)E in (I) and (3)T(2) in (II)] and slightly different 1,3,2-dioxaphospholane ring conformations, viz. envelope in (I) and puckered in (II). Infinite ribbons of 2',3'-cAMP(-) and helical chains of 2',3'-cGMP(-) ions, both formed by O-H...O, N-H...X and C-H...X (X = O or N) hydrogen-bond contacts, characterize (I) and (II), respectively.

Cyclic AMP↗
PubMed2006

Whole spectrum analysis of ligand efficacy at constitutively active human wild-type and S267K 5-HT6 receptors in HEK-293F cells.

INTRODUCTION: Modulation of constitutive activity by the recombinant wild-type human 5-HT6 receptor was investigated with a series of 5-HT6 receptor ligands by monitoring the cAMP signalling pathway. The impact of the mutation S267K near the B(261)BXXB(265) CIII-loop motif was analyzed on the magnitude of constitutive receptor activity as previously conflicting results have been reported. METHODS: The wild-type 5-HT6 receptor plasmid was obtained by PCR and the mutant S267K5-HT6 receptor was constructed by site-directed mutagenesis and stably transfected in HEK-293F cells by electroporation. The cAMP signalling pathway was monitored as a functional read-out to investigate ligands' responses using homogeneous time resolved fluorescence. RESULTS: Constitutive activity was present both at wild-type and mutant S267K 5-HT6 receptors. Negative efficacy (E(max), % versus basal) as observed at nanomolar concentrations with SB-271046 was larger for mutant (-92+/-1%) than wild-type 5-HT6 receptor (-45+/-1%). Ro 04-6790 also demonstrated negative efficacy at the wild-type 5-HT6 receptor with a magnitude similar to SB-271046 but with a 36-fold lower potency. MS-245 demonstrated at nanomolar concentrations intermediate negative efficacy; -48+/-3% and -16+/-2% at mutant and wild-type 5-HT6 receptor, respectively. The 5-HT-mediated cAMP response was blocked by SB-271046, MS-245 and Ro 04-6790 to their respective level of negative efficacy with pKB values fitting with their binding pK(i) values. E-6801 was a highly potent (pEC50: 10.17 to 10.19) and efficacious agonist (+98 to +102% versus 5-HT) at both wild-type and mutant 5-HT6 receptors. DISCUSSION: The recombinant wild-type human 5-HT6 receptor is constitutively active in HEK-293F cells and displays a high resolution to monitor efficacy properties of 5-HT6 receptor ligands. The resolution capacity to differentiate between efficacy properties of 5-HT6 receptor ligands, in particular for negative efficacy, can be further enhanced by monitoring the mutant S267K 5-HT6 receptor.

Cyclic AMP↗